2. Membrane Transporter/Ion Channel Metabolic Enzyme/Protease Apoptosis NF-κB MAPK/ERK Pathway Immunology/Inflammation
  3. Na+/K+ ATPase Glutathione Peroxidase NF-κB p38 MAPK Interleukin Related
  4. 7,8-Dimethoxycoumarin

7,8-Dimethoxycoumarin is a coumarin compound derived from Artemisia caruifolia with oral activity. 7,8-Dimethoxycoumarin inhibits mitochondrial permeability transition pore and H+/K+-ATPase, and exhibits antioxidant, anti-inflammatory, renoprotective, neuroprotective and gastroprotective effects. 7,8-Dimethoxycoumarin reduces lipid peroxidation (TBARS), increases GSH levels, inhibits myeloperoxidase (MPO) activity, and regulates the expression of inflammatory factors by inhibiting the NF‑κB and MAPK pathways. 7,8-Dimethoxycoumarin ameliorates gastric mucosal injury, alleviates renal tissue lesions and relieves neuropathic pain. 7,8-Dimethoxycoumarin can be used in studies related to acute renal failure, trigeminal neuralgia and gastritis.

For research use only. We do not sell to patients.

7,8-Dimethoxycoumarin

7,8-Dimethoxycoumarin Chemical Structure

CAS No. : 2445-80-9

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

7,8-Dimethoxycoumarin Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE 7,8-Dimethoxycoumarin

View All Glutathione Peroxidase Isoform Specific Products:

View All Isoforms
GPX1 GPX4

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

7,8-Dimethoxycoumarin is a coumarin compound derived from Artemisia caruifolia with oral activity. 7,8-Dimethoxycoumarin inhibits mitochondrial permeability transition pore and H+/K+-ATPase, and exhibits antioxidant, anti-inflammatory, renoprotective, neuroprotective and gastroprotective effects. 7,8-Dimethoxycoumarin reduces lipid peroxidation (TBARS), increases GSH levels, inhibits myeloperoxidase (MPO) activity, and regulates the expression of inflammatory factors by inhibiting the NF‑κB and MAPK pathways. 7,8-Dimethoxycoumarin ameliorates gastric mucosal injury, alleviates renal tissue lesions and relieves neuropathic pain. 7,8-Dimethoxycoumarin can be used in studies related to acute renal failure, trigeminal neuralgia and gastritis[1][2][3][4].

IC50 & Target[2][3]

NF-κB

 

IL-6

 

IL-8

 

In Vitro

7,8-Dimethoxycoumarin (DMC) protects human keratinocyte HaCaT cells from TNF-α-induced damage through inhibition of NF-κB activation and MAPK phosphorylation[2].
7,8-Dimethoxycoumarin stimulates melanogenesis via MAPK-mediated MITF upregulation and reduces IL-6, IL-8, and CCL2/MCP-1 expression in TNF-α-treated HaCaT cells[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

7,8-Dimethoxycoumarin Related Antibodies
In Vivo

7,8-Dimethoxycoumarin (50-100 mg/kg; p.o.; daily; 6 consecutive days) ameliorates Cisplatin (HY-17394)-induced acute renal failure in male Sprague Dawley rats in a dose-dependent manner, with the 75 and 100 mg/kg doses producing significant renoprotective effects comparable to Cyclosporin A (HY-B0579)[1].
7,8-Dimethoxycoumarin (100-200 mg/kg; p.o.; daily; 10 consecutive days) dose-dependently attenuates TNF-α-induced trigeminal neuralgia in rats and reversing oxidative stress and histopathological damage[2].
7,8-Dimethoxycoumarin (50-100 mg/kg; i.p.; single dose 1 hour pre-ligation) exerts significant gastroprotective and anti-inflammatory effects in pyloric ligation-induced gastritis in rats at a dose of 100 mg/kg[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague Dawley (male, 180-250 g, cisplatin-induced)[1]
Dosage: 50 mg/kg; 75 mg/kg; 100 mg/kg
Administration: p.o.; daily; 6 consecutive days
Result: Reduced serum BUN, creatinine, urinary NAG, and renal TBARS levels at 50, 75, and 100 mg/kg in a dose‑dependent manner.
Increased FrNa, creatinine clearance, renal GSH, cytochrome c oxidase activity, and ATP levels, while decreasing renal total calcium at 50, 75, and 100 mg/kg.
Attenuated cisplatin‑induced renal histopathological damage; 75 and 100 mg/kg exhibited significant renoprotection comparable to cyclosporin A.
Animal Model: Sprague Dawley (male, 180-250 g, ischemia/reperfusion-induced)[1]
Dosage: 50 mg/kg; 75 mg/kg; 100 mg/kg
Administration: p.o.; daily; 6 consecutive days
Result: Reduced serum BUN, creatinine, urinary NAG, and renal TBARS levels at 50, 75, and 100 mg/kg in a dose‑dependent manner.
Increased FrNa, creatinine clearance, renal GSH, cytochrome c oxidase activity, and ATP levels, while lowering renal total calcium at 50, 75, and 100 mg/kg.
Attenuated ischemia/reperfusion‑induced renal histopathological damage; 75 and 100 mg/kg provided significant protection comparable to cyclosporin A.
Animal Model: Sprague Dawley (male, 180-250 g, cisplatin-induced or ischemia/reperfusion-induced)[1]
Dosage: 25 mg/kg; 50 mg/kg; 100 mg/kg
Administration: p.o.; single dose
Result: Did not produce preventive or protective effects against cisplatin- or ischemia/reperfusion-induced acute renal failure at 25, 50, or 100 mg/kg.
Animal Model: Wistar rats (male, middle-aged 12-14 months, 200-230 g, trigeminal neuralgia induced by single endoneural TNF-α injection)[2]
Dosage: 100 mg/kg; 200 mg/kg
Administration: p.o.; daily; 10 consecutive days
Result: Significantly reversed TNF-α-induced increases in percentage cold chemical sensitivity and percentage mechanical sensitivity response in a dose- and time-dependent manner.
Reduced trigeminal nerve TBARS and TNF-α levels while elevating GSH levels at 100 and 200 mg/kg.
Ameliorated TNF-α-induced histopathological alterations including axonal degeneration, neuronal hypertrophy, and neurovascular injury in trigeminal nerve tissue at both tested doses.
Animal Model: Wistar rats (either sex, fasted 24 hours prior to pyloric ligation)[4]
Dosage: 50 mg/kg; 75 mg/kg; 100 mg/kg
Administration: i.p.; single dose 1 hour pre-ligation
Result: Reduced gastric volume, total acidity, ulcerative index, TBARS levels, and MPO activity at 50, 75, and 100 mg/kg in a dose-dependent manner.
Increased GSH levels at 50, 75, and 100 mg/kg in a dose-dependent manner.
Exhibited effects comparable to omeprazole and N-acetylcysteine at 100 mg/kg.
Molecular Weight

206.19

Formula

C11H10O4
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C1C=CC2=CC=C(OC)C(OC)=C2O1
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (484.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.8499 mL 24.2495 mL 48.4990 mL
5 mM 0.9700 mL 4.8499 mL 9.6998 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.75%

SDS (394 KB)

COA (249 KB) HNMR (133 KB) LCMS (119 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 4.8499 mL 24.2495 mL 48.4990 mL 121.2474 mL
5 mM 0.9700 mL 4.8499 mL 9.6998 mL 24.2495 mL
10 mM 0.4850 mL 2.4249 mL 4.8499 mL 12.1247 mL
15 mM 0.3233 mL 1.6166 mL 3.2333 mL 8.0832 mL
20 mM 0.2425 mL 1.2125 mL 2.4249 mL 6.0624 mL
25 mM 0.1940 mL 0.9700 mL 1.9400 mL 4.8499 mL
30 mM 0.1617 mL 0.8083 mL 1.6166 mL 4.0416 mL
40 mM 0.1212 mL 0.6062 mL 1.2125 mL 3.0312 mL
50 mM 0.0970 mL 0.4850 mL 0.9700 mL 2.4249 mL
60 mM 0.0808 mL 0.4042 mL 0.8083 mL 2.0208 mL
80 mM 0.0606 mL 0.3031 mL 0.6062 mL 1.5156 mL
100 mM 0.0485 mL 0.2425 mL 0.4850 mL 1.2125 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

7,8-Dimethoxycoumarin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

7,8-Dimethoxycoumarin2445-80-9Na+/K+ ATPaseGlutathione PeroxidaseNF-κBp38 MAPKInterleukin RelatedSodium potassium pumpNuclear factor-κBNuclear factor-kappaBILMITFratsMAPKtrigeminal neuralgiaH+/K+-ATPasemitochondrial permeability transition porehuman keratinocyte HaCaT cellsTNF-αacute renal failureInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
7,8-Dimethoxycoumarin
Cat. No.:
HY-N4280
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (394 KB) Français - FR (394 KB) Deutsch - DE (394 KB) Norwegian - NO (394 KB) Español - ES (394 KB) Swedish - SV (394 KB) Italian - IT (394 KB) Korean - KR (394 KB) Portuguese - PT (394 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.